CIA
VRTX icon

CCM Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

CCM Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Buy
26,270
+376
+1% +$167K 1.01% 48
2026
Q1 		$11.6M Sell
25,894
-355
-1% -$166K 1.11% 43
2025
Q4 		$11.9M Sell
26,249
-2,060
-7% -$888K 1.14% 45
2025
Q3 		$11.1M Sell
28,309
-1,306
-4% -$546K 1.09% 48
2025
Q2 		$13.2M Buy
29,615
+2,062
+7% +$950K 1.42% 36
2025
Q1 		$13.4M Buy
27,553
+5,351
+24% +$2.49M 1.64% 31
2024
Q4 		$8.94M Sell
22,202
-7,770
-26% -$3.6M 0.99% 51
2024
Q3 		$13.9M Buy
29,972
+224
+0.8% +$108K 1.55% 34
2024
Q2 		$13.9M Buy
29,748
+563
+2% +$244K 1.64% 26
2024
Q1 		$12.2M Buy
+29,185
New +$12.3M 1.46% 36

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

CCM Investment Advisers's VRTX Position: Q2 2026 in Review

CCM Investment Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $167K and bringing the position to 26,270 shares worth $13M. The position accounts for 1.01% of the portfolio, ranked #48.

CCM Investment Advisers first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $13.9M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • CCM Investment Advisers held 26,270 shares of Vertex Pharmaceuticals worth $13M as of Q2 2026.
  • CCM Investment Advisers bought 376 Vertex Pharmaceuticals shares in Q2 2026, an estimated $167K.
  • Vertex Pharmaceuticals made up 1.01% of CCM Investment Advisers's portfolio in Q2 2026, its #48 holding.
  • CCM Investment Advisers first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • CCM Investment Advisers's Vertex Pharmaceuticals position peaked at $13.9M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CCM Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.